Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs ...

Cross-sector partnership launches EQBMED. Initially funded by PhRMA and established as a cross-sector collaborative, ...

Clinical research evolves to prioritize patient-centered outcomes, integrating accessibility standards in electronic data ...

Joint Clinical Assessment is now a parallel requirement under HTAR. Health technology developers must prepare for a JCA ...

In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer ...

Clinical trials face a critical challenge: bridging the gap between patient curiosity and motivation to participate, ...

In this video interview, Jim Kremidas, executive director, Association for MultiSite Research Corporations (AMRC), discusses ...

As stakeholders debate fair market value in clinical trial budgeting, a new task force works to align sponsors, CROs, and ...

Clinical trial processes lag behind scientific and technological advances. While the science and tools exist to run faster, more inclusive, and efficient trials, outdated mindsets, rigid protocols, ...

Recent analysis explores AI's momentum in drug development, showcasing rapid adoption and significant time savings, despite ...

Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...